FDA Brief

Warning letters Drugs

FDA warning letter to

Laboratorio Magnachem International

High riskIssued Jun 18, 2024Posted Jul 9, 2024Center for Drug Evaluation and Research | CDER

FDA cited Laboratorio Magnachem for CGMP failures and unapproved, misbranded Broncochem cough/cold drugs after a 2023 inspection.

What happened

FDA inspected the facility from November 7 to 10, 2023. Investigators found inadequate investigations of failing stability results, inadequate laboratory and microbial test controls, and uncontrolled lab computer access. FDA also found five Broncochem cough/cold products were unapproved and misbranded, recommended a voluntary recall, and acknowledged the firm had begun recalling some batches.

What FDA found

  1. The firm did not thoroughly investigate failing stability results or missing stability intervals for its drug products.

    21 CFR 211.192
  2. The firm lacked adequate laboratory controls, including validated or verified microbial test methods for objectionable organisms such as Burkholderia cepacia complex.

    21 CFR 211.160(b)
  3. The firm did not restrict access to lab computer systems, allowing staff to delete or modify testing data without traceability and without adequate backups.

    21 CFR 211.68(b)
  4. The Broncochem cough/cold products are unapproved new drugs because they lack FDA-approved applications and do not meet the OTC monograph conditions.

    FD&C Act sections 505(a) and 301(d) (21 U.S.C. 355(a), 331(d))
  5. The Broncochem products are misbranded because they are unapproved new drugs.

    FD&C Act section 502(ee) (21 U.S.C. 352(ee))

What FDA wants

FDA asks the firm to provide comprehensive corrective action plans, retrospective testing of failing results and retained samples, risk assessments, and product-risk actions including customer notifications and recalls; diethylene glycol and ethylene glycol test results are due no later than 30 calendar days from the letter.

Who should pay attention

  • brands or distributors selling Broncochem products in the U.S.
  • companies buying cough/cold syrups or caplets from this manufacturer
  • quality teams relying on supplier COAs for glycerin or other high-risk components

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk